Stockreport

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatme...

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Safety profiles were generally comparable between DOR/ISL and other therapies in these trials RAHWAY, N.J., December 19, 2024 BUSINESS WIRE )--Merck (NYSE: MRK), know [Read more]